NxStage Medical Stock Price, News & Analysis (NASDAQ:NXTM)

$26.03 0.01 (0.04 %)
(As of 11/24/2017 04:00 PM ET)
Previous Close$26.02
Today's Range$25.85 - $26.04
52-Week Range$20.45 - $30.80
Volume88,496 shs
Average Volume813,670 shs
Market Capitalization$1.72 billion
P/E RatioN/A
Dividend YieldN/A
Beta-0.06

About NxStage Medical (NASDAQ:NXTM)

NxStage Medical logoNxStage Medical, Inc. is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets. The In-Center segment includes revenues from the sale of blood tubing sets and needles for hemodialysis, primarily for the treatment of end-stage renal disease patients at dialysis clinics, and needles for apheresis. It markets extracorporeal disposable products under the Medisystems brand. The Services segment includes revenues from dialysis services provided to patients at its NxStage Kidney Care dialysis centers. Its product offerings include Home Dialysis, Next-Generation Hemodialysis System, Critical Care, Next-Generation Critical Care System and In-Center.

Receive NXTM News and Ratings via Email

Sign-up to receive the latest news and ratings for NXTM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Imaging Systems
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:NXTM
CUSIP67072V10
Phone978-687-4700

Debt

Debt-to-Equity RatioN/A
Current Ratio3.29%
Quick Ratio2.19%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$366.38 million
Price / Sales4.71
Cash Flow$0.43 per share
Price / Cash60.48
Book Value$3.21 per share
Price / Book8.11

Profitability

Trailing EPS($0.07)
Net Income$-4,770,000.00
Net Margins-3.60%
Return on Equity-6.54%
Return on Assets-4.25%

Miscellaneous

Employees3,400
Outstanding Shares66,230,000

Frequently Asked Questions for NxStage Medical (NASDAQ:NXTM)

What is NxStage Medical's stock symbol?

NxStage Medical trades on the NASDAQ under the ticker symbol "NXTM."

How were NxStage Medical's earnings last quarter?

NxStage Medical, Inc. (NASDAQ:NXTM) announced its quarterly earnings results on Monday, August, 7th. The medical device company reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by $0.00. The medical device company earned $92.20 million during the quarter, compared to analyst estimates of $96.47 million. NxStage Medical had a negative net margin of 3.60% and a negative return on equity of 6.54%. The firm's revenue for the quarter was up .0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.03) earnings per share. View NxStage Medical's Earnings History.

Where is NxStage Medical's stock going? Where will NxStage Medical's stock price be in 2017?

8 brokerages have issued 12-month price targets for NxStage Medical's shares. Their predictions range from $27.00 to $32.00. On average, they expect NxStage Medical's share price to reach $29.86 in the next year. View Analyst Ratings for NxStage Medical.

What are Wall Street analysts saying about NxStage Medical stock?

Here are some recent quotes from research analysts about NxStage Medical stock:

  • 1. According to Zacks Investment Research, "NxStage Medical, Inc. is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. " (11/14/2017)
  • 2. Northland Securities analysts commented, "We continue to move our PD program forward at an impressive pace…We continue to firmly believe that by keeping our regulatory timelines and pathway confidential, we’re protecting a significant value opportunity. Let me be clear, we both have the opportunity to do great things for patients, bringing new technology to the market that makes PD easier and better." (8/7/2017)
  • 3. Jefferies Group LLC analysts commented, "Home hemodialysis (HHD) in skilled nursing facilities (SNF) is a significant opportunity for NXTM. HHD penetration is already approaching 6% in the most developed states v. less than 2% for the market as a whole; a disparity explained to a large degree by SNF adoption. The regulatory underpinnings can be debated, but even modest assumptions for continued adoption in SNFs supports 20%+ revenue growth at NXTM. We raise our PT to $38, 5x 2018 sales." (2/6/2017)

Are investors shorting NxStage Medical?

NxStage Medical saw a decline in short interest in the month of October. As of October 13th, there was short interest totalling 1,386,386 shares, a decline of 20.2% from the September 29th total of 1,738,099 shares. Based on an average trading volume of 669,391 shares, the short-interest ratio is presently 2.1 days. Currently, 2.1% of the company's stock are sold short.

Who are some of NxStage Medical's key competitors?

Who are NxStage Medical's key executives?

NxStage Medical's management team includes the folowing people:

  • Robert G. Funari, Independent Chairman of the Board (Age 69)
  • Joseph E. Turk Jr., President (Age 49)
  • Jeffrey H. Burbank, Chief Executive Officer, Director (Age 54)
  • Matthew W. Towse CPA, Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer (Age 54)
  • Robert S. Brown, President of NxStage Kidney Care (Age 58)
  • Winifred L. Swan J.D., Senior Vice President, General Counsel (Age 52)
  • Heyward R. Donigan, Independent Director (Age 56)
  • Daniel A. Giannini CPA, , Independent Director (Age 67)
  • Earl R. Lewis, Independent Director (Age 73)
  • Jean K. Mixer, Independent Director (Age 50)

Who owns NxStage Medical stock?

NxStage Medical's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Alpine Associates Management Inc. (6.03%), Magnetar Financial LLC (4.65%), JPMorgan Chase & Co. (2.83%), Gilder Gagnon Howe & Co. LLC (2.38%), Perceptive Advisors LLC (1.91%) and Cortina Asset Management LLC (1.68%). Company insiders that own NxStage Medical stock include Barry M Straube, Craig W Moore, Daniel A Giannini, Earl R Lewis, Jeffrey H Burbank, Joseph E Turk Jr, Joseph E Turk, Jr, Matthew W Towse, Robert S Brown and Winifred L Swan. View Institutional Ownership Trends for NxStage Medical.

Who sold NxStage Medical stock? Who is selling NxStage Medical stock?

NxStage Medical's stock was sold by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, Perceptive Advisors LLC, Sectoral Asset Management Inc, Nationwide Fund Advisors, Point72 Asset Management L.P., Bank of New York Mellon Corp, Wells Fargo & Company MN and Russell Investments Group Ltd.. Company insiders that have sold NxStage Medical company stock in the last year include Craig W Moore, Jeffrey H Burbank, Joseph E Turk Jr, Matthew W Towse, Robert S Brown and Winifred L Swan. View Insider Buying and Selling for NxStage Medical.

Who bought NxStage Medical stock? Who is buying NxStage Medical stock?

NxStage Medical's stock was bought by a variety of institutional investors in the last quarter, including Alpine Associates Management Inc., Magnetar Financial LLC, JPMorgan Chase & Co., State of Wisconsin Investment Board, Cheyne Capital Management UK LLP, ARP Americas LLC, Allianz Asset Management GmbH and Omni Partners LLP. Company insiders that have bought NxStage Medical stock in the last two years include Barry M Straube and Earl R Lewis. View Insider Buying and Selling for NxStage Medical.

How do I buy NxStage Medical stock?

Shares of NxStage Medical can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NxStage Medical's stock price today?

One share of NxStage Medical stock can currently be purchased for approximately $26.03.

How big of a company is NxStage Medical?

NxStage Medical has a market capitalization of $1.72 billion and generates $366.38 million in revenue each year. The medical device company earns $-4,770,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis. NxStage Medical employs 3,400 workers across the globe.

How can I contact NxStage Medical?

NxStage Medical's mailing address is 350 MERRIMACK STREET, LAWRENCE MA, 01843. The medical device company can be reached via phone at 978-687-4700 or via email at [email protected]


MarketBeat Community Rating for NxStage Medical (NXTM)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  225 (Vote Outperform)
Underperform Votes:  171 (Vote Underperform)
Total Votes:  396
MarketBeat's community ratings are surveys of what our community members think about NxStage Medical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for NxStage Medical (NASDAQ:NXTM)

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 1.911.831.922.57
Ratings Breakdown: 2 Sell Rating(s)
8 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
8 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
9 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $29.22$29.22$29.22$29.60
Price Target Upside: 13.26% upside5.34% upside0.39% upside29.34% upside

Consensus Price Target History for NxStage Medical (NASDAQ:NXTM)

Price Target History for NxStage Medical (NASDAQ:NXTM)

Analysts' Ratings History for NxStage Medical (NASDAQ:NXTM)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/8/2017Northland SecuritiesReiterated RatingHold$30.00N/AView Rating Details
10/17/2017Canaccord GenuityReiterated RatingHold$30.00N/AView Rating Details
8/22/2017Leerink SwannDowngradeOutperform -> Market Perform$28.00 -> $30.00HighView Rating Details
8/11/2017BTIG ResearchDowngradeBuy -> NeutralLowView Rating Details
8/9/2017StephensDowngradeOverweight -> Equal Weight$33.00 -> $30.00LowView Rating Details
8/8/2017Jefferies Group LLCDowngradeBuy -> Hold$33.00 -> $30.00MediumView Rating Details
8/7/2017William BlairDowngradeOutperform -> Market PerformMediumView Rating Details
8/7/2017Craig HallumDowngradeBuy -> HoldHighView Rating Details
6/3/2016Piper Jaffray CompaniesReiterated RatingBuy$21.00N/AView Rating Details
5/5/2016Wells Fargo & CompanyReiterated RatingSellN/AView Rating Details
12/11/2015Sterne Agee CRTInitiated CoverageBuyN/AView Rating Details
(Data available from 11/24/2015 forward)

Earnings

Earnings History and Estimates Chart for NxStage Medical (NASDAQ:NXTM)

Earnings by Quarter for NxStage Medical (NASDAQ:NXTM)

Earnings History by Quarter for NxStage Medical (NASDAQ NXTM)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2017Q2 2017($0.03)($0.03)$96.47 million$92.20 millionViewN/AView Earnings Details
5/9/2017Q1 2017($0.03)($0.02)$95.31 million$96.83 millionViewListenView Earnings Details
2/28/2017Q416($0.02)($0.02)$91.82 million$93.01 millionViewListenView Earnings Details
8/4/2016Q216($0.04)($0.03)$89.44 million$92.20 millionViewN/AView Earnings Details
5/4/2016Q116($0.05)($0.02)$88.40 million$89.20 millionViewListenView Earnings Details
2/10/2016Q415($0.04)($0.04)$86.83 million$89.80 millionViewListenView Earnings Details
11/3/2015Q315($0.08)($0.03)$82.06 million$86.50 millionViewN/AView Earnings Details
8/6/2015Q215($0.10)($0.08)$79.89 million$80.30 millionViewListenView Earnings Details
5/6/2015Q115($0.11)($0.09)$77.92 million$79.50 millionViewListenView Earnings Details
2/26/2015Q414($0.10)($0.08)$75.75 million$79.90 millionViewListenView Earnings Details
11/6/2014Q3($0.13)($0.07)$71.83 million$75.30 millionViewN/AView Earnings Details
8/7/2014Q214($0.11)($0.12)$70.52 million$74.10 millionViewN/AView Earnings Details
5/8/2014Q114($0.11)($0.09)$69.44 million$72.20 millionViewN/AView Earnings Details
2/27/2014Q413($0.09)($0.08)$67.66 million$69.40 millionViewN/AView Earnings Details
11/7/2013Q313$0.22($0.08)$124.03 million$66.90 millionViewListenView Earnings Details
7/25/2013Q2 2013($0.07)($0.06)$64.66 million$65.50 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.08)($0.08)$61.14 million$61.60 millionViewN/AView Earnings Details
2/28/2013Q4 2012($0.05)($0.04)$63.54 million$65.00 millionViewN/AView Earnings Details
11/8/2012Q312($0.06)($0.04)$60.90 million$61.00 millionViewN/AView Earnings Details
8/8/2012($0.09)($0.09)ViewN/AView Earnings Details
5/8/2012($0.09)($0.09)ViewN/AView Earnings Details
2/29/2012($0.09)($0.08)ViewN/AView Earnings Details
11/3/2011($0.10)($0.10)ViewN/AView Earnings Details
8/3/2011($0.10)($0.10)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for NxStage Medical (NASDAQ:NXTM)
2017 EPS Consensus Estimate: ($0.03)
2018 EPS Consensus Estimate: $0.11
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.03)($0.02)($0.02)
Q2 20173($0.03)$0.00($0.02)
Q3 20173($0.01)$0.01$0.00
Q4 20173$0.00$0.02$0.01
Q1 20182$0.01$0.02$0.02
Q2 20182$0.01$0.01$0.01
Q3 20182$0.02$0.05$0.04
Q4 20182$0.04$0.05$0.05
(Data provided by Zacks Investment Research)

Dividends

Dividend History for NxStage Medical (NASDAQ:NXTM)

No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for NxStage Medical (NASDAQ NXTM)

Insider Ownership Percentage: 4.70%
Institutional Ownership Percentage: 86.06%
Insider Trades by Quarter for NxStage Medical (NASDAQ:NXTM)
Institutional Ownership by Quarter for NxStage Medical (NASDAQ:NXTM)

Insider Trades by Quarter for NxStage Medical (NASDAQ NXTM)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/15/2017Winifred L SwanSVPSell3,500$25.73$90,055.00View SEC Filing  
10/20/2017Winifred L SwanSVPSell3,500$27.50$96,250.00View SEC Filing  
10/4/2017Joseph E Turk JrPresidentSell1,000$27.56$27,560.00View SEC Filing  
9/20/2017Matthew W TowseSVPSell4,300$27.27$117,261.00View SEC Filing  
9/5/2017Joseph E Turk JrPresidentSell1,000$27.95$27,950.00View SEC Filing  
8/21/2017Matthew W TowseSVPSell4,300$29.22$125,646.00View SEC Filing  
8/15/2017Winifred L SwanSVPSell3,500$29.21$102,235.00View SEC Filing  
8/10/2017Joseph E Turk JrPresidentSell1,000$29.26$29,260.00View SEC Filing  
8/7/2017Joseph E Turk JrPresidentSell24,000$29.64$711,360.00View SEC Filing  
8/3/2017Joseph E Turk JrPresidentSell7,000$22.98$160,860.00View SEC Filing  
7/20/2017Matthew W TowseSVPSell4,300$24.16$103,888.00View SEC Filing  
7/5/2017Joseph E Turk JrPresidentSell1,000$25.19$25,190.00View SEC Filing  
6/20/2017Matthew W TowseSVPSell4,300$23.29$100,147.00View SEC Filing  
6/15/2017Winifred L SwanSVPSell3,500$23.14$80,990.00View SEC Filing  
6/14/2017Joseph E Turk JrPresidentSell1,000$23.74$23,740.00View SEC Filing  
5/22/2017Matthew W TowseSVPSell4,300$21.36$91,848.00View SEC Filing  
5/15/2017Winifred L SwanSVPSell3,500$21.94$76,790.00View SEC Filing  
5/10/2017Joseph E Turk JrPresidentSell250$23.59$5,897.50View SEC Filing  
5/3/2017Joseph E Turk JrPresidentSell1,000$29.95$29,950.00View SEC Filing  
4/20/2017Jeffrey H BurbankCEOSell3,000$27.28$81,840.00View SEC Filing  
4/20/2017Matthew W TowseSVPSell4,300$27.28$117,304.00View SEC Filing  
4/19/2017Jeffrey H BurbankCEOSell3,000$26.65$79,950.00View SEC Filing  
4/13/2017Joseph E Turk JrPresidentSell1,000$26.10$26,100.00View SEC Filing  
4/3/2017Robert S BrownInsiderSell14,397$26.60$382,960.20View SEC Filing  
3/22/2017Jeffrey H BurbankCEOSell3,000$27.42$82,260.00View SEC Filing  
3/21/2017Jeffrey H BurbankCEOSell3,000$27.72$83,160.00View SEC Filing  
3/20/2017Winifred L SwanSVPSell15,723$27.66$434,898.18View SEC Filing  
3/16/2017Craig W MooreDirectorSell1,000$27.93$27,930.00View SEC Filing  
3/8/2017Joseph E Turk JrPresidentSell1,000$27.53$27,530.00View SEC Filing  
3/7/2017Robert S BrownInsiderSell20,000$27.75$555,000.00View SEC Filing  
3/6/2017Robert S BrownInsiderSell6,390$28.01$178,983.90View SEC Filing  
2/23/2017Jeffrey H BurbankCEOSell7,500$28.97$217,275.00View SEC Filing  
2/22/2017Jeffrey H BurbankCEOSell7,500$29.01$217,575.00View SEC Filing  
2/17/2017Joseph E Turk JrPresidentSell6,000$29.66$177,960.00View SEC Filing  
2/15/2017Winifred L SwanSVPSell16,049$28.01$449,532.49View SEC Filing  
2/14/2017Robert S BrownInsiderSell2,448$28.28$69,229.44View SEC Filing  
2/10/2017Joseph E Turk JrPresidentSell3,500$28.36$99,260.00View SEC Filing  
2/8/2017Robert S BrownInsiderSell3,054$27.61$84,320.94View SEC Filing  
2/7/2017Robert S BrownInsiderSell3,117$27.54$85,842.18View SEC Filing  
2/6/2017Robert S BrownInsiderSell16,283$26.87$437,524.21View SEC Filing  
2/2/2017Joseph E Turk JrPresidentSell15,669$26.19$410,371.11View SEC Filing  
2/2/2017Robert S BrownInsiderSell37,347$26.68$996,417.96View SEC Filing  
1/26/2017Robert S BrownInsiderSell42,000$26.05$1,094,100.00View SEC Filing  
1/23/2017Robert S BrownInsiderSell21,615$26.20$566,313.00View SEC Filing  
1/20/2017Matthew W TowseSVPSell4,300$26.19$112,617.00View SEC Filing  
1/18/2017Jeffrey H BurbankCEOSell7,500$27.63$207,225.00View SEC Filing  
1/18/2017Robert S BrownInsiderSell8,183$27.58$225,687.14View SEC Filing  
1/17/2017Jeffrey H BurbankCEOSell7,500$27.52$206,400.00View SEC Filing  
1/17/2017Robert S BrownInsiderSell10,805$27.72$299,514.60View SEC Filing  
1/13/2017Joseph E Turk JrPresidentSell7,500$28.00$210,000.00View SEC Filing  
1/11/2017Joseph E Turk JrPresidentSell1,000$27.77$27,770.00View SEC Filing  
12/20/2016Matthew W TowseSVPSell4,300$25.55$109,865.00View SEC Filing  
12/15/2016Winifred L SwanSVPSell3,500$25.91$90,685.00View SEC Filing  
12/14/2016Jeffrey H BurbankCEOSell7,500$25.68$192,600.00View SEC Filing  
12/13/2016Jeffrey H BurbankCEOSell7,500$25.42$190,650.00View SEC Filing  
12/13/2016Joseph E Turk JrPresidentSell1,000$25.42$25,420.00View SEC Filing  
11/28/2016Joseph E Turk JrPresidentSell12,169$26.01$316,515.69View SEC Filing  
11/23/2016Jeffrey H BurbankCEOSell7,500$24.01$180,075.00View SEC Filing  
11/22/2016Jeffrey H BurbankCEOSell7,500$25.51$191,325.00View SEC Filing  
11/22/2016Winifred L SwanSVPSell3,000$25.51$76,530.00View SEC Filing  
11/21/2016Daniel A GianniniDirectorSell6,449$25.96$167,416.04View SEC Filing  
11/21/2016Matthew W TowseSVPSell4,300$26.23$112,789.00View SEC Filing  
11/17/2016Joseph E Turk JrPresidentSell1,000$25.97$25,970.00View SEC Filing  
11/16/2016Joseph E Turk JrPresidentSell22,500$26.26$590,850.00View SEC Filing  
9/14/2016Craig W MooreDirectorSell3,000$23.31$69,930.00View SEC Filing  
5/12/2016Joseph E Turk JrPresidentSell1,500$17.89$26,835.00View SEC Filing  
5/10/2016Joseph E Turk JrPresidentSell1,057$18.00$19,026.00View SEC Filing  
4/21/2016Joseph E Turk JrPresidentSell2,000$15.73$31,460.00View SEC Filing  
4/14/2016Winifred L SwanSVPSell6,260$16.40$102,664.00View SEC Filing  
4/5/2016Joseph E Turk JrPresidentSell2,500$15.05$37,625.00View SEC Filing  
3/22/2016Joseph E Turk JrPresidentSell2,000$14.34$28,680.00View SEC Filing  
3/14/2016Winifred L SwanSVPSell620$15.69$9,727.80View SEC Filing  
3/10/2016Joseph E Turk JrPresidentSell2,500$15.58$38,950.00View SEC Filing  
2/24/2016Barry M StraubeDirectorBuy1,500$14.20$21,300.00View SEC Filing  
2/24/2016Joseph E Turk JrPresidentSell2,992$14.12$42,247.04View SEC Filing  
2/16/2016Winifred L. SwanSVPSell2,500$14.07$35,175.00View SEC Filing  
2/12/2016Earl R. LewisDirectorBuy21,000$14.63$307,230.00View SEC Filing  
2/10/2016Joseph E. Turk, Jr.PresidentSell991$16.25$16,103.75View SEC Filing  
2/9/2016Joseph E. Turk, Jr.PresidentSell2,500$16.88$42,200.00View SEC Filing  
2/4/2016Joseph E. Turk, Jr.PresidentSell991$19.60$19,423.60View SEC Filing  
1/20/2016Joseph E Turk JrPresidentSell2,000$18.75$37,500.00View SEC Filing  
1/14/2016Winifred L. SwanSVPSell620$19.04$11,804.80View SEC Filing  
1/11/2016Matthew W. TowseSVPSell3,472$20.40$70,828.80View SEC Filing  
1/8/2016Joseph E. Turk, Jr.PresidentSell1,500$21.03$31,545.00View SEC Filing  
1/7/2016Joseph E. Turk, Jr.PresidentSell3,713$20.78$77,156.14View SEC Filing  
12/22/2015Joseph E. Turk, Jr.PresidentSell5,000$20.92$104,600.00View SEC Filing  
12/16/2015Joseph E. Turk, Jr.PresidentSell800$19.99$15,992.00View SEC Filing  
12/15/2015Matthew W. TowseSVPSell2,863$19.51$55,857.13View SEC Filing  
12/14/2015Winifred L. SwanSVPSell2,500$18.90$47,250.00View SEC Filing  
12/10/2015Jeffrey H. BurbankCEOSell9,274$18.94$175,649.56View SEC Filing  
12/8/2015Joseph E. Turk, Jr.PresidentSell2,913$19.38$56,453.94View SEC Filing  
11/20/2015Craig W MooreDirectorSell1,000$20.00$20,000.00View SEC Filing  
11/19/2015Joseph E Turk JrPresidentSell2,000$19.65$39,300.00View SEC Filing  
11/18/2015Craig W MooreDirectorSell4,000$19.60$78,400.00View SEC Filing  
11/16/2015Winifred L. SwanSVPSell2,500$19.65$49,125.00View SEC Filing  
11/12/2015Joseph E. Turk, Jr.PresidentSell4,055$20.44$82,884.20View SEC Filing  
11/10/2015Jeffrey H. BurbankCEOSell10,000$20.75$207,500.00View SEC Filing  
11/10/2015Joseph E. Turk, Jr.PresidentSell7,500$21.03$157,725.00View SEC Filing  
11/10/2015Matthew W. TowseSVPSell2,863$20.32$58,176.16View SEC Filing  
11/9/2015Daniel A GianniniDirectorSell6,593$20.30$133,837.90View SEC Filing  
11/9/2015Jeffrey H. BurbankCEOSell10,000$20.32$203,200.00View SEC Filing  
11/4/2015Joseph E. Turk, Jr.PresidentSell4,826$19.62$94,686.12View SEC Filing  
11/4/2015Matthew W. TowseSVPSell8,591$19.50$167,524.50View SEC Filing  
11/3/2015Robert S. BrowninsiderSell44,400$19.00$843,600.00View SEC Filing  
10/20/2015Joseph E. Turk, Jr.PresidentSell2,000$15.80$31,600.00View SEC Filing  
10/16/2015Jeffrey H. BurbankCEOSell10,000$15.59$155,900.00View SEC Filing  
10/15/2015Jeffrey H. BurbankCEOSell10,000$14.98$149,800.00View SEC Filing  
10/14/2015Winifred L. SwanSVPSell2,500$15.46$38,650.00View SEC Filing  
10/8/2015Joseph E. Turk, Jr.PresidentSell2,839$15.42$43,777.38View SEC Filing  
9/24/2015Joseph E Turk JrPresidentSell2,000$17.26$34,520.00View SEC Filing  
9/17/2015Jeffrey H. BurbankCEOSell10,000$16.18$161,800.00View SEC Filing  
9/16/2015Jeffrey H. BurbankCEOSell10,000$15.99$159,900.00View SEC Filing  
9/15/2015Craig W MooreDirectorSell1,000$16.00$16,000.00View SEC Filing  
9/14/2015Winifred L. SwanSVPSell2,500$16.01$40,025.00View SEC Filing  
9/9/2015Joseph E. Turk, Jr.PresidentSell2,839$16.54$46,957.06View SEC Filing  
8/25/2015Joseph E Turk JrPresidentSell2,000$18.25$36,500.00View SEC Filing  
8/17/2015Robert S BrownInsiderSell10,825$18.30$198,097.50View SEC Filing  
8/14/2015Winifred L SwanSVPSell2,500$18.14$45,350.00View SEC Filing  
8/13/2015Jeffrey H BurbankCEOSell10,000$18.31$183,100.00View SEC Filing  
8/12/2015Jeffrey H BurbankCEOSell10,000$18.03$180,300.00View SEC Filing  
8/12/2015Joseph E Turk JrPresidentSell3,252$17.74$57,690.48View SEC Filing  
7/22/2015Joseph E Turk JrPresidentSell2,000$13.86$27,720.00View SEC Filing  
7/14/2015Winifred L SwanSVPSell2,500$14.71$36,775.00View SEC Filing  
6/23/2015Joseph E Turk JrPresidentSell2,000$15.36$30,720.00View SEC Filing  
6/18/2015Jeffrey H BurbankCEOSell20,000$15.56$311,200.00View SEC Filing  
6/15/2015Winifred L SwanSVPSell2,500$15.48$38,700.00View SEC Filing  
6/10/2015Joseph E Turk JrPresidentSell2,839$16.00$45,424.00View SEC Filing  
5/18/2015Winifred L SwanSVPSell2,500$16.65$41,625.00View SEC Filing  
5/12/2015Jeffrey H BurbankCEOSell10,000$16.44$164,400.00View SEC Filing  
4/21/2015Joseph E Turk JrPresidentSell1,950$18.40$35,880.00View SEC Filing  
4/17/2015Jeffrey H BurbankCEOSell10,000$18.08$180,800.00View SEC Filing  
4/16/2015Jeffrey H BurbankCEOSell10,000$18.31$183,100.00View SEC Filing  
4/8/2015Joseph E Turk JrPresidentSell1,500$18.34$27,510.00View SEC Filing  
3/26/2015Joseph E Turk JrPresidentSell1,150$16.94$19,481.00View SEC Filing  
3/18/2015Jeffrey H BurbankCEOSell20,000$17.40$348,000.00View SEC Filing  
3/10/2015Joseph E Turk JrPresidentSell1,500$16.44$24,660.00View SEC Filing  
2/25/2015Joseph E Turk JrPresidentSell2,082$17.88$37,226.16View SEC Filing  
1/27/2015Joseph E Turk JrPresidentSell2,350$18.70$43,945.00View SEC Filing  
1/14/2015Winifred L SwanSVPSell500$18.44$9,220.00View SEC Filing  
1/13/2015Joseph E Turk JrPresidentSell1,500$18.35$27,525.00View SEC Filing  
1/13/2015Winifred L SwanSVPSell666$18.35$12,221.10View SEC Filing  
12/29/2014Winifred L SwanSVPSell667$18.17$12,119.39View SEC Filing  
12/23/2014Joseph E Turk JrPresidentSell2,350$18.44$43,334.00View SEC Filing  
12/15/2014Joseph E Turk JrPresidentSell2,000$17.45$34,900.00View SEC Filing  
12/15/2014Kevin HershbergerCAOSell8,000$17.19$137,520.00View SEC Filing  
12/10/2014Joseph E Turk JrPresidentSell1,500$17.77$26,655.00View SEC Filing  
12/5/2014Jeffrey H BurbankCEOSell5,000$17.16$85,800.00View SEC Filing  
12/2/2014Robert S BrownInsiderSell34,700$17.44$605,168.00View SEC Filing  
12/1/2014Joseph E Turk JrPresidentSell24,762$17.04$421,944.48View SEC Filing  
12/1/2014Winifred L SwanSVPSell16,667$17.04$284,005.68View SEC Filing  
11/25/2014Joseph E Turk JrPresidentSell3,350$17.59$58,926.50View SEC Filing  
11/14/2014Joseph E Turk JrPresidentSell29,560$17.39$514,048.40View SEC Filing  
11/14/2014Winifred L SwanSVPSell17,167$17.37$298,190.79View SEC Filing  
11/12/2014Joseph E Turk JrPresidentSell26,261$16.27$427,266.47View SEC Filing  
11/12/2014Kevin HershbergerCAOSell11,056$16.58$183,308.48View SEC Filing  
11/7/2014Joseph E Turk JrPresidentSell24,761$16.25$402,366.25View SEC Filing  
11/3/2014Joseph E Turk JrPresidentSell5,717$15.50$88,613.50View SEC Filing  
10/23/2014Joseph E Turk JrPresidentSell3,550$14.55$51,652.50View SEC Filing  
10/23/2014Robert S BrownInsiderSell45,370$14.53$659,226.10View SEC Filing  
9/24/2014Joseph E Turk JrPresidentSell3,550$13.34$47,357.00View SEC Filing  
9/19/2014Jeffrey H BurbankCEOSell2,416$14.00$33,824.00View SEC Filing  
9/19/2014Joseph E Turk JrPresidentSell1,500$14.00$21,000.00View SEC Filing  
9/10/2014Kevin HershbergerCAOSell843$13.58$11,447.94View SEC Filing  
9/8/2014Jeffrey H BurbankCEOSell2,322$14.00$32,508.00View SEC Filing  
9/8/2014Joseph E Turk JrPresidentSell1,500$14.00$21,000.00View SEC Filing  
8/27/2014Joseph E Turk JrPresidentSell2,550$13.06$33,303.00View SEC Filing  
8/15/2014Winifred L SwanSVPSell2,500$13.60$34,000.00View SEC Filing  
8/7/2014Jeffrey H BurbankCEOSell5,000$14.00$70,000.00View SEC Filing  
8/7/2014Joseph E Turk JrPresidentSell1,500$14.00$21,000.00View SEC Filing  
7/24/2014Joseph E Turk JrPresidentSell3,550$13.50$47,925.00View SEC Filing  
7/18/2014Winifred L SwanSVPSell2,000$13.46$26,920.00View SEC Filing  
6/24/2014Joseph E Turk JrPresidentSell3,950$14.43$56,998.50View SEC Filing  
6/20/2014Jeffrey H BurbankCEOSell5,000$14.00$70,000.00View SEC Filing  
6/17/2014Joseph E Turk JrPresidentSell1,500$14.00$21,000.00View SEC Filing  
6/9/2014Winifred L SwanSVPSell9,228$14.00$129,192.00View SEC Filing  
6/5/2014Jeffrey H BurbankCEOSell5,000$14.00$70,000.00View SEC Filing  
6/5/2014Joseph E Turk JrPresidentSell1,500$14.00$21,000.00View SEC Filing  
6/5/2014Winifred L SwanSVPSell7,500$14.00$105,000.00View SEC Filing  
5/29/2014Joseph E Turk JrPresidentSell4,035$13.60$54,876.00View SEC Filing  
5/15/2014Winifred SwanSVPSell9,629$12.80$123,251.20View SEC Filing  
5/14/2014Winifred SwanSVPSell5,000$13.04$65,200.00View SEC Filing  
3/6/2014Robert FunariDirectorBuy10,150$14.72$149,408.00View SEC Filing  
10/21/2013Robert S BrownInsiderSell140,100$14.00$1,961,400.00View SEC Filing  
9/9/2013Thomas SheaSVPSell1,000$12.30$12,300.00View SEC Filing  
8/12/2013Thomas SheaSVPSell1,172$12.93$15,153.96View SEC Filing  
7/8/2013Thomas SheaSVPSell7,000$14.34$100,380.00View SEC Filing  
6/10/2013Thomas SheaSVPSell5,000$13.73$68,650.00View SEC Filing  
5/13/2013Thomas SheaSVPSell15,724$12.67$199,223.08View SEC Filing  
11/13/2012David S UtterbergDirectorSell184,204$11.58$2,133,082.32View SEC Filing  
11/2/2012David S UtterbergDirectorSell34,730$11.13$386,544.90View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for NxStage Medical (NASDAQ NXTM)

Source:
DateHeadline
NxStage Medical Prepares for Fresenius MergerNxStage Medical Prepares for Fresenius Merger
www.fool.com - November 21 at 1:13 PM
$102.29 Million in Sales Expected for NxStage Medical, Inc. (NXTM) This Quarter$102.29 Million in Sales Expected for NxStage Medical, Inc. (NXTM) This Quarter
www.americanbankingnews.com - November 19 at 2:54 PM
NxStage Medical, Inc. (NXTM) Expected to Post Quarterly Sales of $102.29 MillionNxStage Medical, Inc. (NXTM) Expected to Post Quarterly Sales of $102.29 Million
www.americanbankingnews.com - November 19 at 2:50 AM
Winifred L. Swan Sells 3,500 Shares of NxStage Medical, Inc. (NXTM) StockWinifred L. Swan Sells 3,500 Shares of NxStage Medical, Inc. (NXTM) Stock
www.americanbankingnews.com - November 15 at 9:11 PM
NxStage Medical, Inc. (NXTM) Given Consensus Recommendation of "Hold" by BrokeragesNxStage Medical, Inc. (NXTM) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 13 at 10:06 PM
ETFs with exposure to NxStage Medical, Inc. : November 9, 2017ETFs with exposure to NxStage Medical, Inc. : November 9, 2017
finance.yahoo.com - November 12 at 11:14 AM
ETFs with exposure to NxStage Medical, Inc. : November 9, 2017ETFs with exposure to NxStage Medical, Inc. : November 9, 2017
finance.yahoo.com - November 12 at 11:14 AM
NxStage Medical, Inc. (NXTM) Earns Hold Rating from Northland SecuritiesNxStage Medical, Inc. (NXTM) Earns Hold Rating from Northland Securities
www.americanbankingnews.com - November 8 at 3:40 PM
NXTM Crosses Below Key Moving Average LevelNXTM Crosses Below Key Moving Average Level
www.nasdaq.com - November 7 at 4:33 PM
Traders Buy High Volume of NxStage Medical Put Options (NXTM)Traders Buy High Volume of NxStage Medical Put Options (NXTM)
www.americanbankingnews.com - November 6 at 2:28 AM
Eleven Unique NxStage Abstracts Accepted for 2017 Kidney WeekEleven Unique NxStage Abstracts Accepted for 2017 Kidney Week
finance.yahoo.com - November 2 at 7:11 AM
Featured Company News - Shareholders of NxStage Approve Merger with Fresenius Medical CareFeatured Company News - Shareholders of NxStage Approve Merger with Fresenius Medical Care
finance.yahoo.com - October 31 at 7:16 AM
 Brokerages Expect NxStage Medical, Inc. (NXTM) Will Announce Quarterly Sales of $102.29 Million Brokerages Expect NxStage Medical, Inc. (NXTM) Will Announce Quarterly Sales of $102.29 Million
www.americanbankingnews.com - October 30 at 9:38 AM
NxStage Medical, Inc. (NXTM) Short Interest Down 20.2% in OctoberNxStage Medical, Inc. (NXTM) Short Interest Down 20.2% in October
www.americanbankingnews.com - October 29 at 3:26 AM
Nxstage Medical (NXTM) Stockholders Approve Merger Agreement With Fresenius Medica (FMS) - StreetInsider.comNxstage Medical (NXTM) Stockholders Approve Merger Agreement With Fresenius Medica (FMS) - StreetInsider.com
www.streetinsider.com - October 28 at 3:28 PM
NxStage Announces Stockholder Approval Of Merger Agreement With Fresenius Medical CareNxStage Announces Stockholder Approval Of Merger Agreement With Fresenius Medical Care
finance.yahoo.com - October 28 at 10:35 AM
NxStage Medical, Inc. (NXTM) Set to Announce Quarterly Earnings on WednesdayNxStage Medical, Inc. (NXTM) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - October 25 at 8:02 AM
ETFs with exposure to NxStage Medical, Inc. : October 23, 2017ETFs with exposure to NxStage Medical, Inc. : October 23, 2017
finance.yahoo.com - October 24 at 7:57 AM
NxStage Medical, Inc. (NXTM) SVP Sells $96,250.00 in StockNxStage Medical, Inc. (NXTM) SVP Sells $96,250.00 in Stock
www.americanbankingnews.com - October 23 at 7:46 PM
NxStage Announces Winners of Third Annual Nurse Hero AwardNxStage Announces Winners of Third Annual Nurse Hero Award
finance.yahoo.com - October 19 at 7:01 AM
NxStage Medical, Inc. (NXTM) Rating Reiterated by Canaccord GenuityNxStage Medical, Inc. (NXTM) Rating Reiterated by Canaccord Genuity
www.americanbankingnews.com - October 17 at 5:16 PM
Zacks: Brokerages Anticipate NxStage Medical, Inc. (NXTM) Will Announce Quarterly Sales of $102.29 MillionZacks: Brokerages Anticipate NxStage Medical, Inc. (NXTM) Will Announce Quarterly Sales of $102.29 Million
www.americanbankingnews.com - October 11 at 1:54 PM
Zacks Investment Research Downgrades NxStage Medical, Inc. (NXTM) to SellZacks Investment Research Downgrades NxStage Medical, Inc. (NXTM) to Sell
www.americanbankingnews.com - October 10 at 6:56 AM
ETFs with exposure to NxStage Medical, Inc. : October 9, 2017ETFs with exposure to NxStage Medical, Inc. : October 9, 2017
finance.yahoo.com - October 9 at 4:00 PM
NxStage Medical, Inc. breached its 50 day moving average in a Bullish Manner : NXTM-US : October 6, 2017NxStage Medical, Inc. breached its 50 day moving average in a Bullish Manner : NXTM-US : October 6, 2017
finance.yahoo.com - October 7 at 6:47 AM
NxStage Medical, Inc. :NXTM-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017NxStage Medical, Inc. :NXTM-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017
finance.yahoo.com - October 7 at 6:47 AM
NxStage Medical, Inc. (NXTM) President Sells $27,560.00 in StockNxStage Medical, Inc. (NXTM) President Sells $27,560.00 in Stock
www.americanbankingnews.com - October 4 at 8:46 PM
NxStage Medical, Inc. (NXTM) Given Average Recommendation of "Hold" by AnalystsNxStage Medical, Inc. (NXTM) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - September 24 at 6:42 PM
NxStage Medical, Inc. (NXTM) Expected to Announce Quarterly Sales of $102.29 MillionNxStage Medical, Inc. (NXTM) Expected to Announce Quarterly Sales of $102.29 Million
www.americanbankingnews.com - September 22 at 5:18 AM
NxStage Medical, Inc. (NXTM) SVP Matthew W. Towse Sells 4,300 SharesNxStage Medical, Inc. (NXTM) SVP Matthew W. Towse Sells 4,300 Shares
www.americanbankingnews.com - September 21 at 10:32 PM
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Nxstage Medical, Inc. - NXTMSHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Nxstage Medical, Inc. - NXTM
finance.yahoo.com - September 11 at 1:31 AM
FY2017 EPS Estimates for NxStage Medical, Inc. Reduced by Analyst (NXTM)FY2017 EPS Estimates for NxStage Medical, Inc. Reduced by Analyst (NXTM)
www.americanbankingnews.com - September 8 at 6:50 AM
Research Analysts Issue Forecasts for NxStage Medical, Inc.s Q2 2018 Earnings (NXTM)Research Analysts Issue Forecasts for NxStage Medical, Inc.'s Q2 2018 Earnings (NXTM)
www.americanbankingnews.com - September 7 at 11:36 AM
NxStage Medical, Inc. (NXTM) President Sells $27,950.00 in StockNxStage Medical, Inc. (NXTM) President Sells $27,950.00 in Stock
www.americanbankingnews.com - September 5 at 8:52 PM
NxStage Medical (NXTM) vs. Novadaq Technologies (NVDQ) Critical AnalysisNxStage Medical (NXTM) vs. Novadaq Technologies (NVDQ) Critical Analysis
www.americanbankingnews.com - September 3 at 12:04 PM
NxStage Medical, Inc. (NXTM) Receives Average Rating of "Hold" from BrokeragesNxStage Medical, Inc. (NXTM) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - August 30 at 6:42 PM
NxStage Medical Announces FDA Clearance for Solo Home Hemodialysis Using NxStage® System One™NxStage Medical Announces FDA Clearance for Solo Home Hemodialysis Using NxStage® System One™
finance.yahoo.com - August 29 at 6:15 AM
NxStage Medical, Inc. (NXTM) Sees Large Drop in Short InterestNxStage Medical, Inc. (NXTM) Sees Large Drop in Short Interest
www.americanbankingnews.com - August 29 at 1:08 AM
NxStage System One Now in Nine of Top Ten U.S. Nephrology HospitalsNxStage System One Now in Nine of Top Ten U.S. Nephrology Hospitals
finance.yahoo.com - August 25 at 9:32 AM
NxStage Medical, Inc. (NXTM) SVP Sells $125,646.00 in StockNxStage Medical, Inc. (NXTM) SVP Sells $125,646.00 in Stock
www.americanbankingnews.com - August 23 at 8:04 PM
Contrasting NxStage Medical (NXTM) and Novadaq Technologies (NVDQ)Contrasting NxStage Medical (NXTM) and Novadaq Technologies (NVDQ)
www.americanbankingnews.com - August 21 at 4:22 AM
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whether the Sale of NxStage Medical, Inc. to Fresenius Medical Care for $30 Per Share is Fair to ShareholdersINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whether the Sale of NxStage Medical, Inc. to Fresenius Medical Care for $30 Per Share is Fair to Shareholders
finance.yahoo.com - August 17 at 6:23 AM
NxStage Medical, Inc. (NXTM) Expected to Announce Quarterly Sales of $102.79 MillionNxStage Medical, Inc. (NXTM) Expected to Announce Quarterly Sales of $102.79 Million
www.americanbankingnews.com - August 16 at 6:48 AM
NxStage Medical, Inc. (NXTM) SVP Winifred L. Swan Sells 3,500 SharesNxStage Medical, Inc. (NXTM) SVP Winifred L. Swan Sells 3,500 Shares
www.americanbankingnews.com - August 15 at 8:00 PM
See what the IHS Markit Score report has to say about NxStage Medical Inc.See what the IHS Markit Score report has to say about NxStage Medical Inc.
finance.yahoo.com - August 15 at 4:38 PM
NxStage Medical Partners Dialyze Direct for On-Site DialysisNxStage Medical Partners Dialyze Direct for On-Site Dialysis
finance.yahoo.com - August 15 at 5:18 AM
NXSTAGE INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NxStage Medical, Inc.NXSTAGE INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NxStage Medical, Inc.
finance.yahoo.com - August 15 at 5:18 AM
Brokers Issue Forecasts for NxStage Medical, Inc.s FY2017 Earnings (NASDAQ:NXTM)Brokers Issue Forecasts for NxStage Medical, Inc.'s FY2017 Earnings (NASDAQ:NXTM)
www.americanbankingnews.com - August 14 at 5:08 AM
NxStage Medical, Inc. (NXTM) Downgraded by BTIG Research to "Neutral"NxStage Medical, Inc. (NXTM) Downgraded by BTIG Research to "Neutral"
www.americanbankingnews.com - August 13 at 2:52 PM
NxStage Kidney Care and Dialyze Direct to Provide On-Site Dialysis to Skilled Nursing Facility Patients in OhioNxStage Kidney Care and Dialyze Direct to Provide On-Site Dialysis to Skilled Nursing Facility Patients in Ohio
finance.yahoo.com - August 12 at 6:31 AM

Social Media

Financials

Chart

NxStage Medical (NASDAQ NXTM) Chart for Friday, November, 24, 2017
Loading chart…

This page was last updated on 11/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.